Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
Resource
Ann. Oncol., 27,
Journal
Ann. Oncol.
Journal Issue
27
Pages
-
Date Issued
2016
Date
2016
Author(s)
Gandhi, L.
Gadgeel, S.
Shaw, A.
Barlesi, F.
Crino, L.
Yang, J. C-H.
Dingemans, A-M. C.
Kim, D-W.
de Marinis, F.
Schulz, M.
Liu, S.
Fish, S.
Kotb, A.
Ou, S-H. I.